Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q1268941> ?p ?o }
Showing triples 1 to 56 of
56
with 100 triples per page.
- Q1268941 subject Q7334131.
- Q1268941 subject Q8248726.
- Q1268941 subject Q8297683.
- Q1268941 subject Q8301176.
- Q1268941 subject Q8462588.
- Q1268941 subject Q8529693.
- Q1268941 subject Q9052323.
- Q1268941 abstract "Lomitapide (INN, marketed as Juxtapid in the US and as Lojuxta in the EU) is a drug used as a lipid-lowering agent for the treatment of familial hypercholesterolemia, developed by Aegerion Pharmaceuticals.It has been tested in clinical trials as single treatment and in combinations with atorvastatin, ezetimibe and fenofibrate.The US Food and Drug Administration (FDA) approved lomitapide on 21 December 2012, as an orphan drug to reduce LDL cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH).On 31 May 2013 the European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion with a unanimous vote recommending a marketing authorization for lomitapide. On 31 July 2013 the European Commission approved lomitapide as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) apheresis in adult patients with HoFH.".
- Q1268941 atcPrefix "C10".
- Q1268941 atcSuffix "AX12".
- Q1268941 casNumber "182431-12-5".
- Q1268941 casSupplemental "(mesilate)".
- Q1268941 chEBI "72297".
- Q1268941 fdaUniiCode "82KUB0583F".
- Q1268941 iupacName "N-(2,2,2-Trifluoroethyl)-9-[4-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]2-yl]carbonyl]amino]-1-piperidinyl]butyl]9H-fluoren-9-carboxamde".
- Q1268941 pubchem "9853053".
- Q1268941 thumbnail Lomitapide_skeletal.svg?width=300.
- Q1268941 wikiPageExternalLink 203858s000lbl.pdf.
- Q1268941 wikiPageWikiLink Q1367466.
- Q1268941 wikiPageWikiLink Q14890615.
- Q1268941 wikiPageWikiLink Q18029579.
- Q1268941 wikiPageWikiLink Q2711291.
- Q1268941 wikiPageWikiLink Q28749.
- Q1268941 wikiPageWikiLink Q30612.
- Q1268941 wikiPageWikiLink Q417997.
- Q1268941 wikiPageWikiLink Q419074.
- Q1268941 wikiPageWikiLink Q419724.
- Q1268941 wikiPageWikiLink Q424288.
- Q1268941 wikiPageWikiLink Q43656.
- Q1268941 wikiPageWikiLink Q618446.
- Q1268941 wikiPageWikiLink Q668093.
- Q1268941 wikiPageWikiLink Q7334131.
- Q1268941 wikiPageWikiLink Q824258.
- Q1268941 wikiPageWikiLink Q8248726.
- Q1268941 wikiPageWikiLink Q8297683.
- Q1268941 wikiPageWikiLink Q8301176.
- Q1268941 wikiPageWikiLink Q8462588.
- Q1268941 wikiPageWikiLink Q8529693.
- Q1268941 wikiPageWikiLink Q903441.
- Q1268941 wikiPageWikiLink Q9052323.
- Q1268941 wikiPageWikiLink Q955332.
- Q1268941 atcPrefix "10.0".
- Q1268941 atcSuffix "AX12".
- Q1268941 casNumber "182431".
- Q1268941 chebi "72297".
- Q1268941 iupacName "N--9-[4-[4-[[[4'-[1,1'-biphenyl]2-yl]carbonyl]amino]-1-piperidinyl]butyl]9H-fluoren-9-carboxamde".
- Q1268941 pubchem "9853053".
- Q1268941 unii "82".
- Q1268941 type ChemicalSubstance.
- Q1268941 type Drug.
- Q1268941 type ChemicalObject.
- Q1268941 type Thing.
- Q1268941 type Q8386.
- Q1268941 comment "Lomitapide (INN, marketed as Juxtapid in the US and as Lojuxta in the EU) is a drug used as a lipid-lowering agent for the treatment of familial hypercholesterolemia, developed by Aegerion Pharmaceuticals.It has been tested in clinical trials as single treatment and in combinations with atorvastatin, ezetimibe and fenofibrate.The US Food and Drug Administration (FDA) approved lomitapide on 21 December 2012, as an orphan drug to reduce LDL cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH).On 31 May 2013 the European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion with a unanimous vote recommending a marketing authorization for lomitapide. ".
- Q1268941 label "Lomitapide".
- Q1268941 depiction Lomitapide_skeletal.svg.